Toronto - Delayed Quote CAD

Sernova Biotherapeutics Inc (SVA.TO)

0.1100 +0.0050 (+4.76%)

At close: November 6 at 3:59:37 PM EST

Seraxis and Sernova Announce Appointment of Former FDA Medical Officer Dr. Patricia Beaston as Chief Medical Officer of Seraxis and Post Merger BetaNova Biotherapeutics

GlobeNewswire 20d ago

SVA.TO
+4.76%
PSH0.DE

SEOVF
Sernova Biotherapeutics to Participate in Noble Capital Markets’ Emerging Growth Virtual Equity Conference

GlobeNewswire 1mo ago

SVA.TO
+4.76%
SEOVF

PSH
Steven Sangha Announces Voting and Support Agreement for Sernova Biotherapeutics Inc.'s Proposed Business Combination with Seraxis Holdings, Inc.

TMX Newsfile 1mo ago

SVA.TO
+4.76%
SEOVF

PSH0.F
Sernova and Seraxis Enter Definitive Merger Agreement to Create a Differentiated Type 1 Diabetes Islet Cell-Replacement Biotech Company, BetaNova Biotherapeutics

GlobeNewswire 1mo ago

SVA.TO
+4.76%
PSH.DE

SEOVF
Cell Encapsulation Global Market Report 2026-2035 | Features Strategic Profiles of Beta-Cell, Betalin Therapeutics, Beta-O2 Technologies, Diatranz Otsuka, Neurotech, Semma Therapeutics, Sernova, ViaCyte

GlobeNewswire 2mo ago

SVA.TO
+4.76%
Sernova and Seraxis Close US$11.2 Million Financing to Fund Merger to Become BetaNova Biotherapeutics and Advance Type 1 Diabetes Cell Therapy Into Near Term Phase 1/2 Clinical Trial

GlobeNewswire 1mo ago

SVA.TO
+4.76%
PSH.DE

PSH
Sernova Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investor Conference

GlobeNewswire 1mo ago

PSH

SEOVF

SVA.TO
+4.76%
Sernova Biotherapeutics Receives FDA Orphan Drug Designation for Autologous Islet Transplantation for Prevention of Diabetes Due to Total Pancreatectomy

GlobeNewswire 4mo ago

SEOVF

SVA.NE

SVA.TO
+4.76%
Sernova Biotherapeutics Announces Closing of Recently Approved Financings

TMX Newsfile 6mo ago

SEOVF

SVA.NE

SVA.TO
+4.76%
A Diabetes Therapy Just Locked In Its Cell Supplier, and the Race to End Insulin Injections Is Heating Up

CNW Group 3mo ago

AVAI

SEOVF

VRTX
Sernova Biotherapeutics Announces Affirmative Voting Results from 2026 Annual General Meeting of Shareholders

TMX Newsfile 6mo ago

SEOVF
Sernova Biotherapeutics Announces Close of Non-Brokered Private Placement Financing

TMX Newsfile 7mo ago

U.S. markets open in 6h 30m

Sernova Biotherapeutics Inc (SVA.TO)

Seraxis and Sernova Announce Appointment of Former FDA Medical Officer Dr. Patricia Beaston as Chief Medical Officer of Seraxis and Post Merger BetaNova Biotherapeutics

Sernova Biotherapeutics to Participate in Noble Capital Markets’ Emerging Growth Virtual Equity Conference

Steven Sangha Announces Voting and Support Agreement for Sernova Biotherapeutics Inc.'s Proposed Business Combination with Seraxis Holdings, Inc.

Sernova and Seraxis Enter Definitive Merger Agreement to Create a Differentiated Type 1 Diabetes Islet Cell-Replacement Biotech Company, BetaNova Biotherapeutics

Cell Encapsulation Global Market Report 2026-2035 | Features Strategic Profiles of Beta-Cell, Betalin Therapeutics, Beta-O2 Technologies, Diatranz Otsuka, Neurotech, Semma Therapeutics, Sernova, ViaCyte

Sernova and Seraxis Close US$11.2 Million Financing to Fund Merger to Become BetaNova Biotherapeutics and Advance Type 1 Diabetes Cell Therapy Into Near Term Phase 1/2 Clinical Trial

Sernova Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investor Conference

Sernova Biotherapeutics Receives FDA Orphan Drug Designation for Autologous Islet Transplantation for Prevention of Diabetes Due to Total Pancreatectomy

Sernova Biotherapeutics Announces Closing of Recently Approved Financings

A Diabetes Therapy Just Locked In Its Cell Supplier, and the Race to End Insulin Injections Is Heating Up

Sernova Biotherapeutics Announces Affirmative Voting Results from 2026 Annual General Meeting of Shareholders

Sernova Biotherapeutics Announces Close of Non-Brokered Private Placement Financing